News Conference News ESC 2023 ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More Michael O'Riordan September 06, 2023
News Conference News ESC 2023 ESC Focused Update on HF Synthesizes New Trial Data for Practical Use L.A. McKeown September 01, 2023
News ESC 2023 Qiliqiangxin, a Traditional Chinese Medication, Cuts CV Events in HF: QUEST Michael O'Riordan August 27, 2023
News Daily News New AHA/ACC Performance and Quality Metrics for Coronary Revascularization Michael O'Riordan July 28, 2023
News Daily News Pitavastatin Cuts MACE in HIV-Infected Patients: REPRIEVE Michael O'Riordan July 25, 2023
News Daily News Acute MI Patients Without Standard CVD Risk Factors at Higher Risk of Death Michael O'Riordan July 07, 2023
News Daily News Global Numbers Paint Grim Picture of GDMT Uptake, Costs, and HF Outcomes Michael O'Riordan June 23, 2023
News Daily News Obicetrapib Effective When Added to Statins and Ezetimibe: ROSE2 Michael O'Riordan June 14, 2023
News Conference News EAS 2023 Variable Response to Novel PCSK9 Inhibitor Lerodalcibep in LIBERATE-HoFH Michael O'Riordan May 24, 2023
News Conference News EAS 2023 High LDL, Poor Treatment, Early Death: HoFH Registry Paints Grim Picture Michael O'Riordan May 23, 2023
News Conference News SCAI 2023 Repeat Revascularization Not Increased With Solo Ticagrelor: TWILIGHT Analysis L.A. McKeown May 22, 2023
News Daily News Oxidized Phospholipids and Lp(a) Strongly Associated With MACE: CASABLANCA Michael O'Riordan May 03, 2023
News Daily News Low-Dose Polypills Top Other Approaches for Initial BP Control: Meta-analysis Todd Neale April 26, 2023
News Daily News Ezetimibe Plus Moderate-Dose Statins May Aid Compliance in the Elderly Yael L. Maxwell April 03, 2023
News Daily News Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF Todd Neale March 15, 2023
News Conference News ACC 2023 Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes Michael O'Riordan March 04, 2023
News Daily News Longer-Term ASCVD Risk Assessment Best for Younger Patients Michael O'Riordan February 16, 2023